

# Hydrotropic Solubilization of Paclitaxel: Analysis of Chemical Structures for Hydrotropic Property

Jaehwi Lee,<sup>1</sup> Sang Cheon Lee,<sup>1</sup>  
Ghanashyam Acharya,<sup>1</sup> Ching-ger Chang,<sup>1</sup> and  
Kinam Park<sup>1,2</sup>

Received February 26, 2003; accepted March 27, 2003

**Purpose.** To identify hydrotropic agents that can increase aqueous paclitaxel (PTX) solubility and to study the chemical structures necessary for hydrotropic properties so that polymeric hydrotropic agents can be synthesized.

**Methods.** More than 60 candidate hydrotropic agents (or hydrotropes) were tested for their ability to increase the aqueous PTX solubility. A number of nicotinamide analogues were synthesized based on the observation that nicotinamide showed a favorable hydrotropic property. The identified hydrotropes for PTX were used to examine the structure-activity relationship.

**Results.** *N,N*-Diethylnicotinamide (NNDENA) was found to be the most effective hydrotropic agent for PTX. The aqueous PTX solubility was 39 mg/ml and 512 mg/ml at NNDENA concentrations of 3.5 M and 5.95 M, respectively. These values are 5–6 orders of magnitude greater than the intrinsic solubility of  $0.30 \pm 0.02$   $\mu$ g/ml. *N*-Picolylnicotinamide, *N*-allylnicotinamide, and sodium salicylate were also excellent hydrotropes for PTX. Solubility data showed that an effective hydrotropic agent should be highly water soluble while maintaining a hydrophobic segment.

**Conclusions.** The present study identified several hydrotropic agents effective for increasing aqueous solubility of PTX and analyzed the structural requirements for this hydrotropic property. This information can be used to find other hydrotropic compounds and to synthesize polymeric hydrotropes that are effective for PTX and other poorly water-soluble drugs.

**KEY WORDS:** hydrotropic agents; solubilization; poorly water-soluble drug; paclitaxel; structure-activity relationship.

## INTRODUCTION

Poor water solubility of many drugs and drug candidates causes significant problems in producing formulations with sufficiently high bioavailability (1–3). Paclitaxel (PTX) presents a good example of the importance of water solubility. Its use in cancer therapy has been hindered by its low water solubility (4), which has required special formulations utilizing ethanol and Cremophore EL (polyoxyethylated castor oil), which has significant side effects such as hypersensitivity reactions (5). Testing PTX in preclinical tumor model systems is also difficult (6). In addition, the cosolvent mixture is diluted in isotonic saline solution before intravenous administration, and the diluted solution remains stable for only several hours (7). For hydrophobic drugs with poor water solubility, including PTX, several methods have been used to

increase their water solubility. Poorly water-soluble drugs have been formulated into micron- or submicron-size particulate preparations (3), liposomes and micelles (8), and solid dispersions (9,10). Cosolvent systems can increase the drug solubility significantly, but the choices of clinically used solvents are limited to ethylene glycol, dimethylsulfoxide, *N,N*-dimethylformamide, Cremophore, and ethanol (11).

In an attempt to find an alternative or supplementary method for increasing water solubility of poorly soluble drugs, we have examined the possibility of using hydrotropes. Hydrotropic agents (hydrotropes) have been used to increase the water solubility of poorly soluble drugs, and in many instances, the water solubility has increased by orders of magnitude (12). Hydrotropy is a collective molecular phenomenon describing an increase in the aqueous solubility of a poorly soluble compound by addition of a relatively large amount of a second solute (i.e., a hydrotrope) (1). Each hydrotropic agent is effective in increasing the water solubility of selected hydrophobic drugs, and no universal hydrotropic agent has been found to be effective with all hydrophobic drugs. Thus, finding the right hydrotropic agents for a particular hydrophobic drug requires the screening of a large number of candidate hydrotropes. In this study, we examined various candidate agents for their abilities to solubilize PTX so that the structures of effective agents can be used for identification of other hydrotropic agents and for synthesis of hydrotropic polymers.

## MATERIALS AND METHODS

### Materials

PTX was obtained from Samyang Genex Corp. (Taejeon, South Korea). 6-Hydroxynicotinic acid, 1,1'-carbonyldiimidazole (CDI), diethylamine, 3-picolyamine, nicotinoyl chloride hydrochloride, allylamine, acetic anhydride, pyridine, and triethylamine were purchased from Aldrich Chemical Company (Milwaukee, WI) and used without further purification. Methylene chloride was dried and distilled over calcium hydride. Tetrahydrofuran (THF) was distilled from sodium benzophenone before use. *n*-Hexane, diethyl ether, chloroform, and methanol were of reagent grade. All other chemicals were purchased from Fisher Scientific (Pittsburgh, PA). Freshly prepared distilled water was used throughout.

### Synthesis and Characterization of Nicotinamide Analogues

#### Instrumental Analysis

<sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained using a Bruker ARX300 spectrometer at 300 MHz and 75 MHz, respectively. Elemental analysis was performed on a Perkin Elmer Series II CHNS/O Analyzer 2400. UV-VIS spectra were obtained by a Beckman DU® 640 spectrophotometer. Electrospray ionization mass spectrometry (ESI-MS) assay was done using a FinniganMAT LCQ (ThermoFinnigan Corp, San Jose, CA). The electrospray needle voltage was set at 4.5 kV, the heated capillary voltage was set to 10 V, and the capillary temperature to 225°C. Typical background source pressure was  $1.2 \times 10^{-5}$  torr. The sample flow rate was approximately 10  $\mu$ l/min. Nitrogen gas was used for drying. The LCQ was scanned to 2,000 amu for these experiments.

<sup>1</sup> Departments of Pharmaceutics and Biomedical Engineering, Purdue University, West Lafayette, Indiana 47907.

<sup>2</sup> To whom correspondence should be addressed. (e-mail: kpark@purdue.edu)

*N-Picolylnicotinamide*

To a solution of 3-picolylamine (0.1 mol) and pyridine (0.2 mol) in dry methylene chloride (600 ml) was added nicotinoyl chloride hydrochloride (0.1 mol) at 0°C. The reaction mixture was stirred at room temperature for 24 h under nitrogen. After 24 h, the solvent was removed under reduced pressure, and the crude product was dissolved in water, neutralized with sodium bicarbonate, and extracted with chloroform (3 × 200 ml). The solution was dried over anhydrous magnesium sulfate. The solvent was removed at reduced pressure, and the product was isolated by column chromatography on a silica gel using THF/*n*-hexane. Yield was 80%; m.p. 105–107°C;  $\lambda_{\text{max}}$ (THF) 256 nm;  $^1\text{H NMR}$  (DMSO- $d_6$ )  $\delta$  4.52 (d,  $J = 5.8$  Hz, 2H), 7.34 (dd,  $J = 4.8, 7.7$  Hz, 1H), 7.49 (dd,  $J = 4.8, 8.1$  Hz, 1H), 7.72–7.75 (m, 1H), 8.20–8.23 (m, 1H), 8.46 (dd,  $J = 1.0, 4.8$  Hz, 1H), 8.58 (d,  $J = 2.4$  Hz, 1H), 8.70 (dd,  $J = 1.0, 4.8$  Hz, 1H), 9.06 (d,  $J = 2.0$  Hz, 1H), 9.29 (t,  $J = 5.8$  Hz, 1H);  $^{13}\text{C NMR}$  (DMSO- $d_6$ )  $\delta$  40.4, 123.4, 129.6, 134.7, 135.0, 135.1, 148.2, 148.3, 148.5, 148.9, 151.9, 164.9; ESI-MS,  $m/z$  214 ( $[\text{M}+\text{H}]^+$ ); analysis calculated for  $\text{C}_{12}\text{H}_{11}\text{N}_3\text{O}$ : C, 67.59; H, 5.20; N, 19.71. Found: C, 67.73; H, 5.10; N, 19.51.

*N-Allylnicotinamide*

To a stirred solution of allylamine (0.168 mol) in dry methylene chloride (500 ml), nicotinoyl chloride hydrochloride (0.112 mol) and triethylamine (0.225 mol) were added at 0°C. The reaction mixture was stirred at room temperature for 24 h under nitrogen. After 24 h, the solvent was removed under reduced pressure. The brown liquid was dissolved in distilled water and neutralized with sodium bicarbonate, followed by extraction with chloroform (3 × 200 ml). The solvent was removed at reduced pressure, and the crude product was column chromatographed with THF/*n*-hexane on a silica gel to produce a light yellow liquid. Yield was 85%;  $\lambda_{\text{max}}$ (THF) 260 nm;  $^1\text{H NMR}$  (DMSO- $d_6$ )  $\delta$  3.89–3.94 (m, 2H), 5.05–5.20 (m, 2H), 5.82–5.94 (m, 1H), 7.47 (dd,  $J = 5.0, 8.3$  Hz, 1H), 8.20 (m, 1H), 8.68 (dd,  $J = 1.7, 5.0$  Hz, 1H), 8.87 (t,  $J = 5.6$  Hz, 1H), 9.04 (d,  $J = 1.7$  Hz, 1H);  $^{13}\text{C NMR}$  (DMSO- $d_6$ )  $\delta$  41.5, 115.3, 123.3, 129.9, 134.9, 135.0, 148.5, 151.7, 164.6; ESI-MS,  $m/z$  163 ( $[\text{M}+\text{H}]^+$ ); analysis calculated for  $\text{C}_9\text{H}_{10}\text{N}_2\text{O}$ : C, 66.65; H, 6.21; N, 17.27. Found: C, 66.53; H, 6.07; N, 16.97.

*6-Hydroxy-N,N-Diethylnicotinamide*

To a stirred suspension of 6-hydroxynicotinic acid (0.108 mol) in THF (600 ml) was added CDI (0.108 mol) in one portion. The reaction mixture was stirred at reflux under nitrogen. After 24 h, diethylamine (0.216 mol) was added dropwise to the stirred suspension of *N*-(6-hydroxynicotinyl)-imidazole in THF at reflux. The reaction was further maintained for 24 h under nitrogen. After cooling of the reaction mixture to room temperature, 1N sodium hydroxide solution (120 ml) was added. THF was evaporated, and the aqueous solution of the crude product was washed with diethyl ether (5 × 200 ml). The aqueous solution was then neutralized with 1N hydrochloric acid to pH 7 and extracted with chloroform (3 × 200 ml). The solution was dried over anhydrous magnesium sulfate. The solvent was removed at reduced pressure, and the product was isolated by column chromatography on a silica gel using THF/*n*-hexane. Yield was 65%; m.p. 113–115°C;  $\lambda_{\text{max}}$ (THF) 253 nm;  $^1\text{H NMR}$  (DMSO- $d_6$ )  $\delta$  1.09 (t,  $J = 7.2$  Hz, 6H), 3.32 (q,  $J = 7.2$  Hz, 4H), 6.34 (d,  $J = 9.1$  Hz, 1H), 7.45 (dd,  $J = 2.4, 9.1$  Hz, 1H), 7.50 (d,  $J = 2.4$  Hz, 1H);  $^{13}\text{C NMR}$  (DMSO- $d_6$ )  $\delta$  13.3, 41.0, 114.4, 119.3, 135.5, 139.7, 161.9, 166.8; ESI-MS,  $m/z$  195 ( $[\text{M}+\text{H}]^+$ ); analysis calculated for  $\text{C}_{10}\text{H}_{14}\text{N}_2\text{O}_2$ : C, 61.84; H, 7.27; N, 14.42. Found: C, 61.73; H, 7.16; N, 14.47.

*2-Hydroxy-N,N-Diethylnicotinamide*

To a stirred suspension of 2-hydroxynicotinic acid (0.216 mol) in THF (700 ml) was added CDI (0.216 mol) in one portion. The reaction mixture was stirred at reflux under nitrogen. After 24 h, diethylamine (0.323 mol) was added dropwise to the stirred suspension of *N*-(2-hydroxynicotinyl)-imidazole in THF at reflux. The reaction was maintained for 24 h under nitrogen. After cooling of the reaction mixture to room temperature, the solution was concentrated under reduced pressure. The pale yellow precipitate was filtered, washed with diethyl ether, and dried *in vacuo*. Yield was 70%; m.p. 90–92°C;  $\lambda_{\text{max}}$ (THF) 313 nm;  $^1\text{H NMR}$  (DMSO- $d_6$ )  $\delta$  1.00 (t,  $J = 7.2$  Hz, 3H), 1.07 (t,  $J = 7.2$  Hz, 3H), 3.12 (q,  $J = 7.2$  Hz, 2H), 3.35 (q,  $J = 7.2$  Hz, 2H), 6.20 (m, 1H), 7.38 (dd,  $J = 2.4, 6.9$  Hz, 1H), 7.41 (dd,  $J = 2.4, 6.9$  Hz, 1H);  $^{13}\text{C NMR}$  (DMSO- $d_6$ )  $\delta$  12.8, 14.1, 38.4, 42.2, 104.6, 129.3, 136.1, 138.4, 159.2, 166.2; ESI-MS,  $m/z$  195 ( $[\text{M}+\text{H}]^+$ ); analysis calculated for  $\text{C}_{10}\text{H}_{14}\text{N}_2\text{O}_2$ : C, 61.84; H, 7.27; N, 14.42. Found: C, 62.14; H, 7.18; N, 14.42.

*N-Picolylacetamide*

To a stirred solution of acetic anhydride (0.069 mol) in THF (50 ml), a solution of 3-picolylamine (0.046 mol) in THF (20 ml) was added dropwise at room temperature. The reaction mixture was stirred for 5 h under nitrogen. After 5 h, an excess of water was added, and the aqueous solution was neutralized with 1N sodium hydroxide. The solvent was removed at reduced pressure, and the product was isolated by column chromatography on a silica gel using THF/*n*-hexane. Yield was 85%;  $\lambda_{\text{max}}$ (THF) 257 nm;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  1.90 (s, 3H), 4.29 (d,  $J = 5.7$  Hz, 2H), 7.16 (dd,  $J = 4.8, 8.2$  Hz, 1H), 7.39 (s, 1H), 7.54 (m, 1H), 8.34 (dd,  $J = 1.4, 4.8$  Hz, 1H), 8.35 (d,  $J = 1.4$  Hz, 1H);  $^{13}\text{C NMR}$  ( $\text{CDCl}_3$ )  $\delta$  22.7, 40.7, 123.4, 134.2, 135.5, 148.1, 148.6, 170.4; ESI-MS,  $m/z$  151 ( $[\text{M}+\text{H}]^+$ ); analysis calculated for  $\text{C}_8\text{H}_{10}\text{N}_2\text{O}$ : C, 63.98; H, 6.71; N, 18.65. Found: C, 63.85; H, 6.61; N, 18.54.

**NMR Measurement**

The  $^1\text{H NMR}$  spectra of NNDENA in  $\text{D}_2\text{O}$  in the concentration range of 0.0025 to 1.36 M were obtained. The ratios of chemical shifts of nicotinamide protons to the chemical shift of HDO protons (4.63 ppm) were monitored with increasing NNDENA concentrations.

**Solubility Study**

Excess PTX was added to screw-capped vials containing a fixed volume of the hydrotrope solution. This mixture was stirred using a magnetic stirring bar for 24 h at 37°C. An aliquot of the sample was collected, and within 5 s, it was filtered through a 0.2- $\mu\text{m}$  nylon membrane. This immediate filtering process prevented any possible formation of PTX

**Table I.** Paclitaxel Solubilities in the Presence of Various Hydrotropic Agents at 37°C<sup>a</sup>

Hydrotropic agent	Concentration used (M) <sup>b</sup>	PTX solubility (mg/ml)	Standard deviation
None (PTX solubility in pure water)	—	0.0003 <sup>c</sup>	0.0000
<i>N,N</i> -Diethylnicotinamide	3.5	39.071	0.600
<i>N</i> -Picolylnicotinamide	3.5	29.435	1.205
<i>N</i> -Allylnicotinamide	3.5	14.184	0.385
Sodium salicylate	3.5	5.542	0.514
2-Methacryloyloxyethyl phosphorylcholine	2.9	3.199	0.037
Resorcinol	3.5	2.009	0.012
<i>N,N</i> -Dimethylnicotinamide	3.5	1.771	0.026
<i>N</i> -Methylnicotinamide	3.5	1.344	0.006
Butylurea	3.5	1.341	0.071
Pyrogallol	3.5	1.282	0.008
<i>N</i> -Picolyacetamide	3.5	1.084	0.003
Procaine HCl	2.5	0.720	0.005
Nicotinamide	3.5	0.694	0.031
Pyridine	3.5	0.658	0.080
3-Picolyamine	3.5	0.552	0.063
Sodium ibuprofen	1.5	0.500	0.070
Sodium xylenesulfonate	2.5	0.481	0.080
Ethyl carbamate	3.5	0.300	0.028
6-Hydroxy- <i>N,N</i> -diethylnicotinamide	2.0	0.241	0.004
Sodium <i>p</i> -toluenesulfonate	2.5	0.220	0.002
Pyridoxal hydrochloride	2.5	0.216	0.008
1-Methyl-2-pyrrolidone	3.5	0.071	0.002
Sodium benzoate	2.0	0.050	0.006
2-Pyrrolidone	3.5	0.038	0.002
Ethylurea	3.5	0.030	0.003
<i>N,N</i> -Dimethylacetamide	3.5	0.015	0.002
<i>N</i> -Methylacetamide	3.5	0.012	0.001
Isoniazid	1.0	0.009	0.002


<sup>a</sup> Mean  $\pm$  SD,  $n = 3$ , except for PTX solubility in pure water, where  $n = 10$ .

<sup>b</sup> The concentrations less than 3.5 M represent the maximum solubilities of the hydrotropic agent.


<sup>c</sup> The aqueous PTX solubility is  $0.30 \pm 0.02$   $\mu$ g/ml.

particles as a result of the temperature decrease to ambient. The filtrate was diluted with acetonitrile (1:1), and the concentration of PTX was determined by an isocratic reverse-phase HPLC (Agilent 1100 series, Agilent Technologies, Wilmington, DE) using a Symmetry column (Waters Corp.,

Milford, MA) at 25°C. The mobile phase consisted of acetonitrile–water (45:55 v/v) with a flow rate of 1.0 ml/min. A diode array detector was set at 227 nm and linked to Chem-Station software for data analysis. The PTX concentrations in the samples were obtained from a calibration curve.



**Fig. 1.** Paclitaxel solubility as a function of the molar concentration of *N,N*-diethylnicotinamide. The solubility of paclitaxel at 5.95 M of *N,N*-diethylnicotinamide is 512.6 mg/ml. The inserted plot shows the paclitaxel solubility as a function of the log concentration of *N,N*-diethylnicotinamide.



**Fig. 2.** The ratio of chemical shifts of nicotinamide protons to the chemical shift of HDO protons in D<sub>2</sub>O as a function of the concentration of *N,N*-diethylnicotinamide. H-2, H-4, H-5, and H-6 indicate the proton position of the nicotinamide ring of *N,N*-diethylnicotinamide.




Fig. 3. Chemical structure of paclitaxel.

## RESULTS AND DISCUSSION

### Paclitaxel Solubility by Hydrotropes

Because of its noted therapeutic potential and very low water solubility, PTX was chosen to examine hydrotropic properties of various agents in this study. The exact mechanisms involved in solubilization of PTX and other poorly soluble drugs by hydrotropic agents are not clearly understood, so it is difficult to predict the structural requirements of hydrotropes suitable for solubilizing PTX. For this reason, a large number of candidate agents were screened. Table I lists the agents tested and the corresponding water solubilities of PTX measured in the presence of those agents. Our preliminary study suggested that even good hydrotropes required a hydrotropic concentration of approximately 3 M. For this reason, a concentration of 3.5 M was used for all agents to compare their hydrotropic properties under the same condition. The concentrations of some agents listed in Table I are smaller than 3.5 M because of their limited solubility. Table I clearly identifies a number of hydrotropic agents effective for increasing the water solubility of PTX.

The aqueous solubility of PTX at 37°C was determined to be  $0.30 \pm 0.02 \mu\text{g/ml}$ . Thus, a PTX concentration of 39 mg/ml by *N,N*-diethylnicotinamide (NNDENA) in Table I indicates more than 100,000-fold increase in aqueous solubility. Equally effective was *N*-picolylnicotinamide. *N*-Allylnicotinamide, sodium salicylate, and 2-methacryloyloxyethyl phosphorylcholine increased the PTX solubility by four

orders of magnitude. Other hydrotropes that resulted in an aqueous PTX solubility more than 1 mg/ml were resorcinol, *N,N*-dimethylnicotinamide, *N*-methylnicotinamide, butylurea, pyrogallol, and *N*-picolylnicotinamide. The PTX solubility of 0.3 mg/ml by ethyl carbamate appears to be much smaller than that by NNDENA but still represents a 1,000-fold increase.

Another 35 agents not listed in Table I showed paclitaxel solubilities of 0.005 mg/ml (or 5  $\mu\text{g/ml}$ ) or less. They are, in the descending order of solubilizing effect, nipecotamide (3.5 M), citric acid (2.0 M), sodium gentsiate (1.0 M), *N*-isopropylacrylamide (1.5 M), methylurea (3.5 M), 1,3-diamino-2-hydroxypropane-*N,N,N',N'*-tetramethylacetate (3.0 M), thiourea (2.5 M), 1-methylnicotinamide iodide (1.0 M),  $\alpha$ -cyclodextrin (0.15 M), sodium thiocyanate (8.6 M), urea (6.0 M), caffeine (0.1 M), glyceryl triacetate (0.2 M), glycerin (3.5 M), adenosine (0.005 M),  $\gamma$ -cyclodextrin (0.17 M),  $\beta$ -cyclodextrin (0.02 M), diisopropylnicotinamide (0.05 M), pyridine-3-sulfonic acid (1.0 M), *o*-benzoic acid sulfimide (0.01 M), 2,6-pyridinedicarboxamide (0.0025 M), 3,4-pyridinedicarboxamide (0.025 M), 4-aminosalicylic acid (0.005 M), L-tryptophan (0.05 M), salicylaldehyde (0.1 M), sucrose (2.0 M), L-lysine (2.0 M), 4-aminobenzoic acid sodium salt (2.5 M), D-sorbitol (3.0 M), sodium L-ascorbate (3.0 M), sodium propionate (3.5 M), sodium acetate (4.0 M), 2-hydroxy-*N,N*-diethylnicotinamide (0.2 M), 2-hydroxy-*N*-picolylnicotinamide (0.0035 M), and 6-hydroxy-*N*-picolylnicotinamide (0.08 M).

### Hydrotropic Property of NNDENA

The hydrotropic property of NNDENA was examined in more detail. Figure 1 shows the paclitaxel solubility as a function of the NNDENA concentration. NNDENA at 5.95 M increased the PTX concentration to 512 mg/ml (equivalent to 0.6 M because the molecular weight of PTX is 854 g/mol), and this corresponds to 10 NNDENA molecules per paclitaxel molecule dissolved. At the concentration of hydrotropes used in Table I, however, more than 100 hydrotropic agents are necessary for effective solubilization of PTX. The inserted plot in Fig. 1 shows the solubility increase of PTX as a function of the log concentration of NNDENA in the range of

Table II.

Hydrotropic agent	Conc. used (M)	PTX solubility (mg/ml)	Structure
<i>N,N</i> -Diethylnicotinamide	3.5	39.07	
	2.0	0.98	
	0.2	0.001	
6-Hydroxy- <i>N,N</i> -diethylnicotinamide	2.0 <sup>a</sup>	0.24	
2-Hydroxy- <i>N,N</i> -diethylnicotinamide	0.2 <sup>a</sup>	0.00	

<sup>a</sup>The maximum solubility of the hydrotropic agent.

0.0028 to 0.5 M. The water solubility of PTX begins to increase at 0.11 M of NNDENA, although the increase is small compared to higher concentrations of NNDENA.

Because the dissolution of PTX in NNDENA is expected to occur through association of NNDENA molecules, self-association of NNDENA molecules was examined using NMR. Figure 2 shows the NNDENA concentration dependence of the ratio of chemical shifts of nicotinamide protons to the chemical shift of HDO protons in D<sub>2</sub>O. As the concentration of NNDENA increased to about 0.1 M, the ratios of chemical shifts of all protons of the nicotinamide ring started to decrease. The data indicate that NNDENA self-associates via the vertical plane-to-plane interaction of the aromatic rings. The crossover point in Fig. 2 can be described as the minimum hydrotropic concentration (MHC), which is the threshold concentration of self-aggregate formation. The MHC value of NNDENA in the aqueous media was estimated to be 0.12 M. Interestingly, this MHC value is almost the same as the concentration of 0.11 M where NNDENA begins to exhibit the solubilizing ability for PTX in aqueous solutions.









### Structural Analysis of Hydrotropic Property for PTX

To gain insights into the structural requirements necessary for hydrotrophy, chemical structures of various agents listed in Table I were analyzed for their ability to increase aqueous PTX solubility. The structure of PTX is shown in Fig. 3. A few common features of good hydrotropes for PTX were identified.

#### High Water Solubility of Hydrotropic Agents

The main criterion for effective hydrotrophy is high water solubility of the hydrotropic agent. If the water solubility is low (e.g., less than 2 M), the hydrotropic property is not observed to be significant. At 2.0 M, PTX solubility was higher in NNDENA than in 6-hydroxy-*N,N*-diethylnicotinamide. The PTX solubility in NNDENA was greatly increased with increasing the NNDENA concentration. 2-Hydroxy-*N,N*-diethylnicotinamide with the maximum water solubility of only 0.2 M did not have any PTX-solubilizing effect. The following example shows the importance of water solubility of hydrotropic agents on increasing aqueous PTX solubility (Table II).

Table III.

Hydrotropic agent	Conc. used (M)	PTX solubility (mg/ml)	Structure
Sodium salicylate	3.5	5.54	
Pyrogallol (1,2,3-trihydroxybenzene)	3.5	1.28	
Nicotinamide	3.5	0.69	
3-Picolylamine	3.5	0.55	
Nipicotamide	3.5	0.005	
<i>N,N</i> -Dimethylacetamide	3.5	0.015	
<i>N</i> -Isopropylacrylamide	1.5 <sup>a</sup>	0.004	
1,3-Diamino-2-hydroxypropane- <i>N,N,N',N'</i> -tetramethylacetate	3.0 <sup>a</sup>	0.004	

<sup>a</sup>The maximum solubility of the hydrotropic agent

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.